Pınar GÜRKAYNAK, Salih CESUR, Şerife ALTUN DEMİRCAN, Şükran SEVİM, Çiğdem ATAMAN HATİPOĞLU, Sami KINIKLI, Gül GÜRSOY

Sürekli ayaktan periton diyalizi hastasında polimicrobiyal infektif endokarditi takiben gelişen karbapeneme dirençli, çoklu ilaca dirençli Acinetobacter baumannii’ye bağlı olarak gelişen peritonit

Karbapeneme dirençli, çoklu ilaca diençli Acinetobacter baumannii (A.baumannii) infeksiyonları sağlık bakımı ile ilişkili infeksiyonların önemli bir etkeni olup, mortalite ve morbidite nedenidir. Çoklu ilaca dirençli A.baumannii’ye bağlı peritonit nadiren bildirilmektedir. Çoklu ilaca dirençli A.baumannii’ye bağlı olarak gelişen peritoniterin tedavisi güçtür.Bu yazıda, 60 yaşında kronik böbrek yetmezliği nedeniyle periton diyalizi uygulanan bir kadın hastada polimikrobiyal infektif endokarditi takiben A.baumannii’ye bağlı olarak gelişen ve mortal seyreden peritonit bildirilmiş ve literatür gözden geçirilmiştir.

Anahtar Kelimeler:

Acinetobacter baumannii, peritonit, çoklu ilaca direnç, tedavi

Peritonitis due to carbapenem resistant, multidrug resistant Acinetobacter baumannii in a patient with continuous ambulatory peritoneal dialysis following the polymicrobial infective endocarditis

Carbapenems resistant, multi drug resistant Acinetobacter baumannii (A.baumannii) infections are important health-care-associated infections and cause mortality and morbidity. Peritonitis due to multidrug resistant A.baumannii is rarely reported. Treatment of peritonitis due to multidrug resistant A.baumannii is difficult. In this article, peritonitis due to A.baumannii following the polymicrobial infective endocarditis in a female patient who underwent peritoneal dialysis due to chronic renal insufficiency at the age of 60 years has been reported and the literature has been reviewed.

Keywords:

Acinetobacter baumannii, peritonitis, multi-drug resistance, treatment,

PDF

___

Acinetobacter infection: Treatment and prevention. https://www.uptodate.com/contents/acinetobacter-infection-treatment-and-prevention
Phillips M. Acinetobacter Species. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th edi. Elsevier Company: 2552-2558.
Blanco N, Harris AD, Rock C, Johnson JK, ve ark. Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission. Antimicrob Agents Chemother. 2017; 62(1) pii: e01631-17.
Almomani BA, McCullough A, Gharaibeh R, Samrah S, Mahasneh F. Incidence and predictors of 14-day mortality in multidrug-resistant Acinetobacter baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015; 9(12): 1323-30.
Zhang W, Wu YG, Qi XM, Dai H, Lu W, Zhao M. Peritoneal dialysis-related peritonitis with Acinetobacter baumannii: a review of seven cases. Perit Dial Int. 2014; 34(3): 317-21.
Fitzpatrick MA, Esterly JS, Postelnick MJ, Sutton SH. Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam. Ann Pharmacother. 2012; 46(7-8): e17.
Chao CT, Lee SY, Yang WS,ve ark. Acinetobacter peritoneal dialysis peritonitis: a changing landscape over time. PLoS One. 2014; 9 (10): e110315.
Zarakolu P, Ayaz ÇM, Metan G. Various antibiotic combinations against carbapenem resistant Acinetobacter baumannii infections and in vitro synergy test results (2002-2016). Mikrobiyol Bul. 2018; 52(2): 190-197.
Warner WA, Kuang SN, Hernandez R, ve ark. Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA. BMC Infect Dis. 2016; 16: 194.
Salehi B, Goudarzi H, Nikmanesh B, Houri H, Alavi-Moghaddam M, Ghalavand Z. Emergence and characterization of nosocomial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii isolates in Tehran, Iran. J Infect Chemother. 2018; 24(7): 515-523.
Begum S, Hasan F, Hussain S, Ali Shah A. Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pak J Med Sci. 2013; 29(5): 1253-8.
García-Granja PE, López J, Vilacosta I, Ortiz-Bautista C, Sevilla T, Olmos C, ve ark. Polymicrobial Infective Endocarditis: Clinical Features and Prognosis. Medicine (Baltimore). 2015; 94(49): e2000.
Chrissoheris MP, Libertin C, Ali RG, Ghantous A, Bekui A, Donohue T. Endocarditis complicating central venous catheter bloodstream infections: a unique form of health care associated endocarditis. Clin Cardiol. 2009; 32(12): E48-54.
Vincent LL, Otto CM. Infective Endocarditis: Update on Epidemiology, Outcomes, and Management. Curr Cardiol Rep. 2018; 20(10): 86.
Cai Y, Yang D, Wang J, Wang R. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model. J Antimicrob Chemother. 2018; 1; 73(2): 456-461.
Dinc G, Demiraslan H, Elmali F, Ahmed SS, Alp E, Doganay M. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol. 2015; 38(1): 67-73.
Tas MY, Oguz MM, Ceri M. Acinetobacter lwoffii peritonitis in patient on automated peritoneal dialysis: a case report and review of the literature. Case Rep Nephrol. 2017: 5760254.
Htay H, Cho Y, Pascoe EM, Hawley C, Clayton PA, Borlace M. Outcomes of Acinetobacter peritonitis in peritoneal dialysis patients: a multicenter registryanalysis. Perit Dial Int. 2018; 38(4): 257-265.
Li PH, Cheng VC, Yip T, Yap DY, Lui SL, Lo WK. Epidemiology and Clinical Characteristics of Acinetobacter Peritoneal Dialysis-Related Peritonitis in Hong Kong-With a Perspective on Multi-Drug and Carbapenem Resistance. Perit Dial Int. 2017; 37(2): 177-182.
Atas DB, Velioglu A, Asicioglu E, Tigen E. Peritoneal Dialysis-Related Peritonitis With Acinetobacter ursingii. Ther Apher Dial. 2016; 20 (2): 205-6.